Rapid Onset Liver Injury Due to Azacitidine Through Possibly a Unique Mechanism of Hypoperfusion of the Liver.

IF 0.9 Q3 MEDICINE, GENERAL & INTERNAL

Journal of investigative medicine high impact case reports Pub Date : 2025-01-01 Epub Date: 2025-05-21 DOI:10.1177/23247096251344720

Dilara Hatipoglu, Arsia Jamali, Emily Sheng, K Rajender Reddy

引用次数: 0

Abstract

Azacitidine and venetoclax are important anti-neoplastic agents used in the treatment of acute myeloid leukemia. Azacitidine has been implicated to cause nonhepatic ischemic injury. Here we report a case of severe, short latency drug-induced liver injury following the infusion of azacitidine and venetoclax in a patient which was subsequently mitigated through pretreatment with a vasodilatory agent.

查看原文本刊更多论文

阿扎胞苷引起的快速肝损伤可能是一种独特的肝脏灌注不足机制。

阿扎胞苷和venetoclax是治疗急性髓系白血病的重要抗肿瘤药物。阿扎胞苷与非肝性缺血性损伤有关。在这里，我们报告了一例严重的，短潜伏期药物性肝损伤后，输注阿扎胞苷和维托克拉克斯的病人，随后减轻了预处理与血管舒张剂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of investigative medicine high impact case reports MEDICINE, GENERAL & INTERNAL-

CiteScore

1.90

自引率

0.00%

发文量

165

审稿时长

12 weeks

期刊介绍： The AFMR is committed to enhancing the training and career development of our members and to furthering its mission to facilitate the conduct of research to improve medical care. Case reports represent an important avenue for trainees (interns, residents, and fellows) and early-stage faculty to demonstrate productive, scholarly activity.